Psilocybin for Depression

Psilocybin — the active compound in psychedelic mushrooms — has shown genuine promise as a treatment for depression in clinical trials, including the first Phase 3 trial to hit its primary endpoint in June 2025. Here's what the evidence actually shows, what it doesn't, and where the science is heading.

Depression is one of the most treatment-resistant conditions in medicine. Roughly a third of people with major depressive disorder don't respond adequately to antidepressants — a category clinicians call treatment-resistant depression, or TRD. For that group, options narrow fast: higher doses, different medications, electroconvulsive therapy. For decades, that was more or less the end of the road.

That's the gap psilocybin research is aimed at. Unlike conventional antidepressants, which typically work by increasing serotonin availability over weeks or months, psilocybin appears to produce rapid, significant shifts in depressive symptoms — sometimes after just one or two sessions. The mechanism isn't fully understood, but researchers believe it involves a temporary disruption of the default mode network, the brain system associated with self-referential thinking and rumination, which tends to be overactive in depression.

[INTERNAL LINK: What Is the Default Mode Network — and Why Do Psychedelics Affect It?]

Research into psilocybin for depression stalled for decades after psychedelics were federally prohibited in 1970. The modern wave of studies began in earnest at Imperial College London and Johns Hopkins University in the 2010s, initially in small, carefully screened patient groups.

Those early trials were open-label — meaning both researchers and participants knew what was being administered — which limits how much can be concluded. But the results were striking enough to justify larger investment. Patients with long-standing, treatment-resistant depression reported significant reductions in symptoms after one or two psilocybin sessions, with effects that persisted for weeks to months. For many participants, it was the most relief they had experienced from any treatment.

The research established two things clearly: psilocybin is physiologically safe in controlled settings, and the preliminary signal on depression was strong enough to warrant Phase 2 and Phase 3 trials.

[INTERNAL LINK: What Happens in a Psychedelic Therapy Session?]

The most rigorous early evidence came from a large randomized controlled trial published in the New England Journal of Medicine in 2022, led by researchers at Imperial College London. The study compared a 25mg dose of psilocybin, a 10mg dose, and a placebo — with all participants receiving psychological support.

At the 25mg dose, participants showed meaningful reductions in depression severity compared to placebo. The results were statistically significant and clinically meaningful, representing the first large-scale, blinded evidence that psilocybin could outperform a control condition for treatment-resistant depression.

Importantly, the trial also highlighted something the science still has to grapple with: blinding is difficult with psilocybin. Participants generally know whether they've had a psychedelic experience, which introduces the possibility that expectation is doing some of the work. Designing around that problem remains one of the central methodological challenges in the field.

The most significant development in psilocybin research came in June 2025, when Compass Pathways announced that its Phase 3 trial — the largest and most rigorous study of synthetic psilocybin for depression to date — hit its primary endpoint.

The trial, called COMP005, dosed 258 participants with treatment-resistant depression across 32 sites in the United States. A single 25mg dose of synthetic psilocybin demonstrated a highly statistically significant reduction in symptom severity compared to placebo, with a clinically meaningful difference in depression scores at the six-week mark.

No unexpected safety issues or imbalance in suicidal ideation were observed between treatment groups.

Phase 3 is the final trial stage before a company can apply for FDA approval. Compass has stated it plans to engage with the FDA on the basis of these results. The FDA has already granted psilocybin Breakthrough Therapy designation — a status designed to accelerate the development and review of drugs that show substantial improvement over existing treatments for serious conditions.

This doesn't mean approval is imminent or guaranteed. But it moves psilocybin meaningfully closer to the clinic than it has ever been.

[INTERNAL LINK: What Is Compass Pathways?]

[INTERNAL LINK: What Does FDA Approval Actually Mean for Psychedelic Medicine?]

Honest reading of the evidence requires some precision about what's still unknown.

Most of the trials so far have focused on treatment-resistant depression — patients for whom other options have failed. The evidence for psilocybin as a first-line treatment for general depression is much thinner. Researchers have studied it in this context, but the trial sizes are smaller and the results less conclusive.

The question of durability is also open. Many trials measure outcomes at six weeks or three months. What happens at one year, or two? Some follow-up data is encouraging, but the long-term picture is still being built.

And the therapy component matters more than most headlines suggest. Psilocybin therapy is not a pill you take and wait — it requires psychological support before, during, and after the session. Researchers caution against the popular narrative that it acts as a brain "reset," leading to unrealistic expectations of quick fixes. The drug appears to create a window of neuroplasticity — a period where the brain is more open to change — but converting that into lasting improvement typically requires work.

[INTERNAL LINK: What Is Integration Therapy After a Psychedelic Experience?]

Over 130 clinical trials on the therapeutic potential of psilocybin have been initiated in the last two decades, sponsored by more than 100 different institutions. Thirty-nine of those trials are specifically focused on treatment-resistant depression or major depressive disorder. medrxiv

The pipeline is larger and better-funded than at any point in history. Compass's Phase 3 result will likely accelerate regulatory conversations across multiple jurisdictions, not just the US. Other companies and academic institutions are running parallel trials at different doses and with different therapeutic models.

The honest summary: psilocybin for depression is no longer an experimental curiosity. It's an active area of clinical development with Phase 3 evidence behind it, and a regulatory path that, while uncertain, now exists.